Rheumatology International

, Volume 30, Issue 3, pp 331–340 | Cite as

Evaluation of the short-term efficacy of NSAIDs on patients with active ankylosing spondylitis in daily practice: a 3-month, longitudinal, observational study

  • Muhammet Cinar
  • Ayhan Dinc
  • Ismail Simsek
  • Hakan Erdem
  • Bayram Koc
  • Salih Pay
  • Selim Kilic
Original Article


The objective of the study was to investigate the response rate to non-steroidal anti-inflammatory drugs (NSAIDs) and the clinical parameters that might predict this response in patients with active ankylosing spondylitis. This is a prospective, observational, 3-month study that was conducted in a single center. Ninety-five consecutive patients with active ankylosing spondylitis were included in the study. Full dose NSAIDs (indometacin 150 mg daily or acemethazine 180 mg daily) were given to patients. Relevant clinical data of all patients’ were recorded at the beginning and on three consecutive monthly visits. At the end of the study period, patients who respond to NSAIDs were determined. Demographic, clinical, and laboratory parameters that might influence the response to the NSAIDs were investigated. The response rate to the full-dose NSAIDs according to the ASAS20 in patients with active ankylosing spondylitis was found as 29.5%. Similarly, 20.0% of the patients were responders according to the ASAS40 criteria, whereas 5.6% of the patients responded according to the 5-out-of-6 criteria at week 12. Patients who responded to the treatment were found to be younger at the study entry (P = 0.001) and had shorter disease duration (P < 0.001). Due to the markedly lower rate of response to the NSAIDs in patients with active ankylosing spondylitis, early identification of those patients who does not respond to NSAIDs and subsequent decision regarding the institution of second-line treatments (anti-TNF) may be of great value in the prevention of irreversible changes that might develop in most of the patients.


Ankylosing spondylitis Non-steroidal anti-inflammatory drugs Therapy 



The authors thank Yavuz Sanisoglu, PhD, as well as clinical members of the Division of Rheumatology, Gulhane School of Medicine, for assistance with the conduct of the study.


  1. 1.
    Anandarajah A, Ritchlin CT (2005) Treatment update on Spondyloarthropathy. Curr Opin Rheumatol 17:247–256. doi: 10.1097/01.bor.0000159926.42761.dd CrossRefPubMedGoogle Scholar
  2. 2.
    Dougados M (1990) Diagnosis and monitoring of spondylarthropathy. Compr Ther 16:52–56PubMedGoogle Scholar
  3. 3.
    Gossec I, van der Heijde D, Melian A et al (2005) Efficacy of cyclo-oxygenase-2 inhibition by etoricoxib and naproxen on the axial manifestations of ankylosing spondylitis in the presence of peripheral arthritis. Ann Rheum Dis 64:1563–1567. doi: 10.1136/ard.2004.029611 CrossRefPubMedGoogle Scholar
  4. 4.
    Braun J, Sieper J (2006) Spondylarthritides. Z Rheumatol 65(7):613–632. doi: 10.1007/s00393-006-0116-6 CrossRefPubMedGoogle Scholar
  5. 5.
    Dougados M, Béhier JM, Jolchine I et al (2001) Efficacy of celecoxib, a cyclooxygenase 2-specific inhibitor in the treatment of ankylosing spondylitis. A six-week controlled study with comparison against placebo and against a conventional nonsteroidal antiinflammatory drug. Arthritis Rheum 44(1):180–185. doi: 10.1002/1529-0131(200101)44:1<180::AID-ANR24>3.0.CO;2-K CrossRefPubMedGoogle Scholar
  6. 6.
    Dougados M, Gueguen A, Nakache JP et al (1999) Ankylosing spondylitis: what is the optimum duration of a clinical study? A one year versus a 6 weeks non-steroidal anti-inflammatory drug trial. Rheumatology 38:235–244. doi: 10.1093/rheumatology/38.3.235 CrossRefPubMedGoogle Scholar
  7. 7.
    Wanders A, van der Heijde D, Landewe R et al (2005) Inhibition of radiographic progression in ankylosing spondylitis (AS) by continuous use of NSAIDs. Arthritis Rheum 52:1756–1765. doi: 10.1002/art.21054 CrossRefPubMedGoogle Scholar
  8. 8.
    Dougados M, Dijkmans B, Khan M et al (2002) Conventional treatments for ankylosing spondylitis. Ann Rheum Dis 61:40–50Google Scholar
  9. 9.
    Cohen MD (2004) Raising expectations for arthritis treatment. Biologic response modifiers are making remission possible. Postgrad Med 116(5):41–42CrossRefPubMedGoogle Scholar
  10. 10.
    Braun J, Brandt J, Listing J et al (2002) Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 359:1187–1193. doi: 10.1016/S0140-6736(02)08215-6 CrossRefPubMedGoogle Scholar
  11. 11.
    Brandt J, Khariouzov A, Listing J et al (2003) Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum 48(6):1667–1675. doi: 10.1002/art.11017 CrossRefPubMedGoogle Scholar
  12. 12.
    Braun J, Pham T, Sieper J et al (ASAS Working Group) (2003) International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis. Ann Rheum Dis 62:817–824. doi: 10.1136/ard.62.9.817 CrossRefPubMedGoogle Scholar
  13. 13.
    Braun J, Davis J, Dougados M et al (ASAS Working Group) (2006) First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis. Ann Rheum Dis 65(3):316–320. doi: 10.1136/ard.2005.040758 CrossRefPubMedGoogle Scholar
  14. 14.
    Rudwaleit M, Listing J, Brandt J et al (2004) Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis. Ann Rheum Dis 63(6):665–670. doi: 10.1136/ard.2003.016386 CrossRefPubMedGoogle Scholar
  15. 15.
    van der Linden S, Valkenburg HA, Cats A (1984) Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 27(4):361–368. doi: 10.1002/art.1780270401 CrossRefPubMedGoogle Scholar
  16. 16.
    Garrett S, Jenkinson T, Kennedy LG et al (1994) A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 21(12):2286–2291PubMedGoogle Scholar
  17. 17.
    Calin A, Garrett S, Whitelock H et al (1994) A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 21(12):2281–2285PubMedGoogle Scholar
  18. 18.
    Jenkinson TR, Mallorie PA, Whitelock HC et al (1994) Defining spinal mobility in ankylosing spondylitis (AS). The Bath AS Metrology Index. J Rheumatol 21(9):1694–1698PubMedGoogle Scholar
  19. 19.
    Jones SD, Steiner A, Garrett SL et al (1996) The Bath Ankylosing Spondylitis Patient Global Score (BAS-G). Br J Rheumatol 35(1):66–71. doi: 10.1093/rheumatology/35.1.66 CrossRefPubMedGoogle Scholar
  20. 20.
    Heuft-Dorenbosch L, Spoorenberg A, van Tubergen A et al (2003) Assessment of enthesitis in ankylosing spondylitis. Ann Rheum Dis 62(2):127–132. doi: 10.1136/ard.62.2.127 CrossRefPubMedGoogle Scholar
  21. 21.
    Stewart MW, Palmer DG, Knight RG (1990) A self-report articular index measure of arthritic activity: investigations of reliability, validity and sensitivity. J Rheumatol 17(8):1011–1015PubMedGoogle Scholar
  22. 22.
    Khan MA (2003) Clinical features of ankylosing spondylitis. In: Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME, Weicman ME (eds) Rheumatology, 3rd edn. Mosby, Spain, pp 1161–1181Google Scholar
  23. 23.
    Zochling J, Braun J (2005) Management and treatment of ankylosing spondylitis. Curr Opin Rheumatol 17(4):418–425. doi: 10.1097/01.bor.0000163194.48723.64 CrossRefPubMedGoogle Scholar
  24. 24.
    Anderson JJ, Baron G, van der Heijde D et al (2001) Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum 44(8):1876–1886. doi: 10.1002/1529-0131(200108)44:8<1876::AID-ART326>3.0.CO;2-F CrossRefPubMedGoogle Scholar
  25. 25.
    Dougados M (2001) Treatment of spondyloarthropathies. Recent advances and prospects in 2001. Joint Bone Spine 68(6):557–563. doi: 10.1016/S1297-319X(01)00328-1 CrossRefPubMedGoogle Scholar
  26. 26.
    Dougados M, Revel M, Khan MA (1998) Spondylarthropathy treatment: progress in medical treatment, physical therapy and rehabilitation. Baillieres Clin Rheumatol 12(4):717–736. doi: 10.1016/S0950-3579(98)80046-0 CrossRefPubMedGoogle Scholar
  27. 27.
    Dougados M, Nguyen M, Caporal R et al (1994) Ximoprofen in ankylosing spondylitis. A double blind placebo controlled dose ranging study. Scand J Rheumatol 23(5):243–248. doi: 10.3109/03009749409103723 CrossRefPubMedGoogle Scholar
  28. 28.
    Jajic I, Nekora A, Chadri HA (1982) Pirprofen, indomethacin and placebo in ankylosing spondylitis. Double-blind comparison. Nouv Presse Med 11(33):2491–2493PubMedGoogle Scholar
  29. 29.
    Sturrock RD, Hart FD (1974) Double-blind cross-over comparison of indomethacin, flurbiprofen, and placebo in ankylosing spondylitis. Ann Rheum Dis 33(2):129–131. doi: 10.1136/ard.33.2.129 CrossRefPubMedGoogle Scholar
  30. 30.
    Batlle-Gualda E, Figueroa M, Ivorra J et al (1996) The efficacy and tolerability of aceclofenac in the treatment of patients with ankylosing spondylitis: a multicenter controlled clinical trial. Aceclofenac Indomethacin Study Group. J Rheumatol 23(7):1200–1206PubMedGoogle Scholar
  31. 31.
    Calin A, Edmunds L, Kennedy LG (1993) Fatigue in ankylosing spondylitis—why is it ignored? J Rheumatol 20(6):991–995PubMedGoogle Scholar
  32. 32.
    Dernis-Labous E, Messow M, Dougados M (2003) Assessment of fatigue in the management of patients with ankylosing spondylitis. Rheumatology (Oxford) 42(12):1523–1528. doi: 10.1093/rheumatology/keg421 CrossRefGoogle Scholar
  33. 33.
    Zochling J, Bohl-Buhler MH, Baraliakos X et al (2006) Nonsteroidal anti-inflammatory drug use in ankylosing spondylitis—a population-based survey. Clin Rheumatol 25(6):794–800. doi: 10.1007/s10067-005-0132-y CrossRefPubMedGoogle Scholar
  34. 34.
    Zochling J, van der Heijde D, Burgos-Vargas R et al (2006) Assessment in AS’ international working group; European League Against Rheumatism. ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 65(4):442–452. doi: 10.1136/ard.2005.041137 CrossRefPubMedGoogle Scholar
  35. 35.
    Davis JC Jr, Van Der Heijde D, Braun J et al (2003) Enbrel Ankylosing Spondylitis Study Group. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum 48(11):3230–3236. doi: 10.1002/art.11325 CrossRefPubMedGoogle Scholar
  36. 36.
    Gorman JD, Sack KE, Davis JC Jr (2002) Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med 346(18):1349–1356. doi: 10.1056/NEJMoa012664 CrossRefPubMedGoogle Scholar
  37. 37.
    van der Heijde D, Kivitz A, Schiff MH et al (ATLAS Study Group) (2006) Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 54(7):2136–2146. doi: 10.1002/art.21913 CrossRefPubMedGoogle Scholar
  38. 38.
    Hyrich KL, Watson KD, Silman AJ et al (2006) Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford) 45(12):1558–1565. doi: 10.1093/rheumatology/kel149 CrossRefGoogle Scholar
  39. 39.
    Gunal EK, Sarvan FO, Kamali S et al (2008) Low frequency of HLA-B27 in ankylosing spondylitis patients from Turkey. Joint Bone Spine 75(3):299–302. doi: 10.1016/j.jbspin.2007.06.021 CrossRefPubMedGoogle Scholar
  40. 40.
    Cinar M, Dinc A, Simsek I et al (2008) The rate and significance of Mediterranean fever gene mutations in patients with ankylosing spondylitis: a three-month, longitudinal clinical study. Rheumatol Int 29(1):37–42. doi: 10.1007/s00296-008-0637-1 CrossRefPubMedGoogle Scholar
  41. 41.
    Oniankitan O, Ranaivo N, Carton L et al (2005) Poorly and well controlled spondyloarthropathies: a comparison of 2 groups of patients. J Rheumatol 32(1):77–79PubMedGoogle Scholar
  42. 42.
    Hardo PG, Chalmers DM, Jakeways M et al (1993) Management of NSAIDs-related dyspepsia in the community. Br J Clin Pract 47(5):241–242PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  • Muhammet Cinar
    • 1
  • Ayhan Dinc
    • 2
    • 4
  • Ismail Simsek
    • 2
  • Hakan Erdem
    • 2
  • Bayram Koc
    • 1
  • Salih Pay
    • 2
  • Selim Kilic
    • 3
  1. 1.Division of Internal MedicineGulhane Military School of MedicineAnkaraTurkey
  2. 2.Division of RheumatologyGulhane Military School of MedicineAnkaraTurkey
  3. 3.Department of Epidemiology and Public HealthGulhane Military School of MedicineAnkaraTurkey
  4. 4.AnkaraTurkey

Personalised recommendations